William Blair analyst Brandon Vazquez has reiterated their bullish stance on PEN stock, giving a Buy rating on November 7.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Penumbra’s promising growth prospects. The recent discussions with Dr. Adham Karim regarding the STORM-PE trial have reinforced the potential benefits for the thrombectomy market, with Penumbra poised to be a leading beneficiary. The trial’s findings suggest that more healthcare providers may adopt mechanical thrombectomy for pulmonary embolism, potentially increasing the demand for Penumbra’s Lightning system.
Moreover, the establishment of new PERT teams could significantly expand the market, uniquely positioning Penumbra to capitalize on its innovative CAVT technology. The anticipation of a significant product launch next year further supports the company’s growth trajectory. Despite the need for continued development, the current valuation, trading at seven times the projected 2026 sales, underpins the Outperform rating, reflecting confidence in Penumbra’s strategic direction and market potential.
In another report released on November 7, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $299.00 price target.